跳至主要内容
临床试验/NCT01828905
NCT01828905已完成不适用

A Prospective, Multicenter, Randomized Study Investigating the Use of CERAMENT™|BONE VOID FILLER as Bone Graft Substitute in Tibia Plateau Fractures

Johannes Gutenberg University Mainz32 个研究点 分布在 1 个国家目标入组 137 人开始时间: 2013年4月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
137
试验地点
32
主要终点
SF-12 Physical Component Summary (PCS) at week 26

研究概览

简要总结

The aim of the study is to compare fracture healing, quality of life, pain, and cost of care of the use of CERAMENT™|BONE VOID FILLER as bone graft substitute to the use of autologous cancellous bone graft (iliac crest) in the treatment of patients with tibia fractures treated by internal fixation and void reconstruction.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients with traumatic, closed, depression fracture of the proximal tibia (limited to AO type B2 & B3)
  • solitary trauma
  • candidate for bone grafting
  • patients between the age of 18 and 65 years
  • written informed consent obtained before any study-related activities
  • patients with communicative ability to understand the procedure and participate in the study and comply with the follow up program

排除标准

  • patients with multiple injuries
  • polytrauma patients
  • compartment syndrome
  • previous iliac crest bone graft harvesting
  • local infection at the site of implantation
  • chronic pain disease
  • malignancy
  • rheumatoid arthritis
  • chronic cortisone intake
  • X-ray diagnostics not available, fracture cannot be classified
  • clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation
  • a pre-existing calcium metabolism disorder (e.g. hypercalcemia)
  • known hyperthyroidism or autonomous thyroid adenoma
  • history of serious reaction to iodine based radio contrast agents
  • women who are pregnant or breastfeeding
  • irreversible coagulopathy or bleeding disorder
  • history of physical or psychological condition that contraindicates the use of an investigational device or render the patient at high risk from treatment complications
  • history of hypersensitivity to the investigational device or any of its ingredients
  • participation in other clinical trials during the present clinical trial or within the last 1 month

研究组 & 干预措施

Cerament

Experimental

CERAMENT™|BONE VOID FILLER as bone graft substitute

干预措施: CERAMENT™|BONE VOID FILLER (Device)

Bone graft

Active Comparator

Autologous cancellous bone graft (iliac crest)

干预措施: Autologous cancellous bone graft (Procedure)

结局指标

主要结局

SF-12 Physical Component Summary (PCS) at week 26

时间窗: 26 weeks

Global pain VAS score at week 26

时间窗: 26 weeks

次要结局

  • SF-12 PCS and MCS at visit 5(6 weeks)
  • Utilisation of costs of care related resources(26 weeks)
  • SF-12 PCS and MCS at visit 4(1 week)
  • Bone healing(1, 6, 12 and 26 weeks)
  • SF-12 PCS and MCS at visit 6(12 weeks)
  • SF-12 PCS and MCS at visit 7(26 weeks)

研究者

发起方
Johannes Gutenberg University Mainz
申办方类型
Other
责任方
Principal Investigator
主要研究者

Univ.-Prof. Pol M. Rommens

Head of Department of Trauma Surgery, Director of the Center for Musculoskeletal Surgery

Johannes Gutenberg University Mainz

研究点 (32)

Loading locations...

相似试验